



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area

Citation for published version:

Wood, C, Hollingsworth, KG, Hughes, E, Punniyakodi, S, Muni-Lofra, R, Mayhew, A, Mitchell, RT, Guglieri, M, Cheetham, T & Straub, V 2021, 'Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area', *European Journal of Endocrinology*, vol. 184, no. 1, pp. 67–79. <https://doi.org/10.1530/EJE-20-0709>

Digital Object Identifier (DOI):

[10.1530/EJE-20-0709](https://doi.org/10.1530/EJE-20-0709)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

European Journal of Endocrinology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



**Pubertal induction in adolescents with DMD is associated with high satisfaction,
gonadotropin release and increased muscle contractile surface area.**

Wood Claire L^{1,2}, Hollingsworth Kieren G², Hughes Eric², Punniyakodi Sadha³, Muni-Lofra Robert^{2,4}, Mayhew Anna^{2,4}, Mitchell Rod⁵, Guglieri Michela^{2,4}, Cheetham Tim D^{1,2*}, Straub Volker^{2,4*}

*Denotes equal contribution as senior author

¹Department of Paediatric Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne

²Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK

³ Department of Paediatrics, Nobles Hospital, Isle of Man, IM4 4RJ

⁴John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK

⁵ MRC Centre for Reproductive Health, Queens Medical Research Institute, Edinburgh

Correspondence to: Claire L Wood. Department of Paediatric Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. Email: Claire.wood@ncl.ac.uk

Keywords: Duchenne muscular dystrophy, muscle, testosterone, puberty

Short title: Testosterone in DMD

Clinical trial registration: Clinical trials.gov- NCT02571205, EudraCT- 2015-003195-68

Word count: 3451

Abstract

Background

Pharmacological doses of glucocorticoids (GC) reduce inflammation and preserve muscle function in boys with Duchenne muscular dystrophy (DMD). Delayed puberty and bone fragility are consequences of GC treatment. The aim of this study was to determine the acceptability of a 2-year pubertal induction regimen using 4-weekly testosterone injections and examine changes in physique, bone integrity, muscle pathology (assessed by magnetic resonance imaging) and muscle function.

Methods

15 prepubertal males with DMD, aged 12-17 years and receiving GC, were treated with an incremental testosterone regimen for 2 years. Participants completed a Treatment Satisfaction Questionnaire (TSQM). Data on BMI, bone density, muscle pathology and function were collected at baseline and 2 years later.

Results

Testosterone injections were well tolerated, with high TSQM scores. Baseline BMI z-score was 2.16 (0.90) and 1.64 (1.35) 2 years later. Median testosterone levels were 9.7nmol/l (IQR 5.7-11.1) 6 – 9 months after the last injection with an associated increase in testicular volume. Lumbar spine z-score was 0.22 (SD 2.21) at baseline and 0.35 (SD 2.21) after 2 years. Upper and lower limb muscle contractile cross sectional area increased in all participants during the trial ($p=0.05$ and $p<0.01$ respectively). There was a reduction in T2 relaxation times in most muscle groups with stable upper limb muscle function.

Conclusion

Incremental monthly testosterone injections were well tolerated, promoted endogenous testosterone production and had a positive impact on the skeleton and contractile muscle bulk with evidence suggesting a beneficial impact on the underlying disease process.

1 Introduction

2 Duchenne muscular dystrophy (DMD) is a life-limiting genetic disorder that affects 1 in
3 approximately 4000 newborn boys in the UK and occurs due to mutations in the *DMD* gene
4 (1). Absence of the gene product, dystrophin, leads to increased muscle cell fragility and a
5 cycle of degeneration and repair with inflammatory change and replacement of muscle
6 fibres with fibrosis and fat (2). Pharmacological doses of glucocorticoids (GC) – either
7 prednisolone or deflazacort – have had a beneficial impact on longevity and quality of life in
8 DMD (3). Glucocorticoids stabilise muscle strength and have positive effects on
9 cardiovascular and respiratory function (4) and help to reduce scoliosis (5). Unfortunately
10 long-term high dose GC therapy has side-effects that include slow growth, weight gain,
11 osteopaenia, secondary hypoadrenalism (6) and effects on mood (7). GC also prevent the
12 normal progression into puberty, which can have significant psychological consequences.
13 Exogenous androgen has been used for many years in boys with pubertal delay and is
14 increasingly being used in adolescents with DMD (8). Exogenous androgen can have an
15 anabolic effect on a range of different tissues and could mitigate some of the deleterious
16 effects of GC on muscle, bone and psychological well-being. The increased life expectancy
17 and changing expectations of adolescents with DMD underlines the importance of effective
18 DMD management at this time. As yet, no one has examined the psychological,
19 developmental and skeletal effects of testosterone in a prospective manner with a detailed
20 examination of bone and muscle phenotype. A retrospective audit identified 14 boys who
21 had been treated with testosterone for induction of puberty and highlighted the lack of
22 consensus in terms of regimen, length of treatment or age at initiation (8). This study
23 investigated the efficacy and tolerability of a 2-year regimen of incremental, intramuscular
24 testosterone to induce puberty in a cohort of GC-treated adolescents with DMD.

25 **Methods**

26 **Participants**

27 Participants were from a single centre study that followed 15 adolescents with DMD and
28 delayed puberty as they were treated with testosterone. Full details of the clinical trial and
29 protocol have been published (9). Briefly, 15 prepubertal males between 12 and 17 years old
30 were treated with a stepwise regimen of testosterone injections every 4 weeks. Data were
31 collected to determine the effectiveness and tolerability of the treatment regimen. Inclusion
32 and exclusion criteria are in the Supplementary Methods section.

33

34 **Outcomes**

35 ***Primary outcome***

36 The primary outcome measure was Treatment Satisfaction Questionnaire for Medication
37 (TSQM) (10).

38 ***Secondary outcomes***

39 The secondary outcome measures were:

- 40 • Auxological assessment including height, weight and pubertal status (11)
- 41 • Biochemical assessment of pubertal stage
- 42 • Bone age
- 43 • Muscle cross-sectional area (CSA), contractile cross-sectional area (cCSA) and fat
44 fraction (FF) determined by muscle MRI of upper and lower limbs, and T2 relaxation
45 time of the upper limb
- 46 • Motor performance evaluated using North Star Ambulatory Assessment (NSAA) and
47 Performance of Upper Limb (PUL)

- 48 • Bone mineral adjusted density of the lumbar spine and total body (minus head) using
49 Dual-energy x-ray absorptiometry (DXA)

50

51 **Testosterone regimen**

52 The incremental testosterone regimen involved the administration of testosterone
53 (Sustanon 250) by deep intramuscular injection over a 2-year period:

- 54 • Sustanon 50 mg (0.2 ml) every 4 weeks for 12 weeks
55 • Sustanon 100 mg (0.4 ml) every 4 weeks for 40 weeks
56 • Sustanon 150 mg (0.6 ml) every 4 weeks for 24 weeks
57 • Sustanon 250 mg (1 ml) every 4 weeks for 28 weeks

58

59 **Assessment**

60 ***Patient satisfaction***

61 The TSQM is self-administered and used at baseline and 6 monthly thereafter. It is a 14-item
62 instrument, yielding four subscale scores: global satisfaction, effectiveness, adverse events
63 and convenience and has been validated for adults with chronic disease (10). The total score
64 (excluding side-effects domain as these are only answered if the participant felt there were
65 associated side-effects) was the primary outcome measure.

66 ***Clinical assessment***

67 Height/arm span and weight were measured. Target height was calculated using: (mother +
68 father's height)/2 +13cm. Testicular size was assessed using a Prader orchidometer and
69 pubertal staging determined using Tanner Staging criteria (11). Assessments were conducted
70 by CW or TC and cross-checked > 75% patients.

71 ***Biochemical gonadal / androgen status***

72 Biochemical pubertal status was determined by measuring morning (pre-10.00) serum
73 testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH)
74 concentrations at 0,6,12,18,24,27 and 30-33 months. Levels were also measured between 6
75 and 9 months after their last testosterone injection, as part of routine clinical follow-up.

76 ***Bone age***

77 Bone age was assessed at baseline and 2 years using a radiograph of the left wrist and
78 reported by a consultant radiologist (12).

79 ***Motor function and muscle strength***

80 All participants performed PUL (Version 2.0) for assessing upper limb performance (13) and
81 ambulatory patients also undertook the NSAA (14).

82 ***Bone mineral density***

83 DXA scans were conducted annually using a Lunar iDXA (GE Lunar Corp, Madison, WI USA) to
84 assess lean versus total body mass and enable calculation of bone mineral content (BMC),
85 adjusted for age, size and gender. Adjusted z-scores of lumbar spine (L1-4) and total body
86 (minus head) were recorded.

87 ***MRI data acquisition and image processing***

88 Imaging was performed on a 3.0T scanner (detailed protocols in Supplementary Methods).
89 Briefly, quantitative Dixon FF imaging was collected using fivefold compressed sensing
90 acceleration (15, 16). For the upper limb, quantitative Dixon FF imaging and T2 relaxation
91 time imaging (a surrogate of muscle inflammation (17)) was performed and maps processed.
92 Regions of interest (ROIs) were defined for the upper and lower limb for multiple image
93 slices and FF and T2 relaxation times were calculated together as area-weighted averages.
94 CSA and cCSA were also calculated to quantify the area of viable muscle tissue remaining

95 (18). Results are presented for muscle groups across all participants, and for individual
96 participants across all their muscle groups.

97 All participants consented to an MRI scan at baseline, 1 year and 2 years. Six healthy male
98 controls, matched by bone age (as all participants in the trial had delayed puberty and bone
99 age), underwent the same MRI protocol.

100 **Statistical Analysis and approvals**


101 This was an observational study and the primary outcome (treatment satisfaction) was not
102 subject to a power calculation. The recruitment target was pragmatic and reflected the local
103 population of boys with DMD and pubertal delay who were not already enrolled in a clinical
104 trial. All data are presented as mean \pm SD unless stated otherwise. Independent t-tests were
105 used to compare baseline measurements of DMD boys to healthy control participants.

106 Paired t-tests (or Wilcoxon rank-sum techniques if variables not normally distributed) were
107 used to compare outcome measures before and after testosterone administration. Statistical
108 significance was taken to be $p < 0.05$. Stata v15 was used for statistical analysis.

109 The study was approved by York Research Ethics Committee. Informed consent was
110 obtained from the patient if ≥ 16 years and from the parent/guardian with patient assent if
111 ≤ 16 years.

112 **Results**

113 **Study flowchart**



114

115 **Baseline characteristics**

116 Recruitment commenced in December 2015 until November 2016. 17 patients were

117 approached, 16 agreed to take part and were screened and 15 were eligible (see flowchart

118 and protocol (9)). The last participant's final visit was February 2019. Participants were aged

119 12.0-16.9 years (mean 13.8 years, mean bone age 9.4 years) at baseline (Table I). Controls

120 were matched to bone age; their chronological age ranged from 7.9-12.9 years (mean 10.0

121 years), all controls were prepubertal. 3/15 participants were non-ambulant at baseline. All

122 participants had been on GC therapy for a mean of 8.1 years at recruitment (Table II);

123 regimens were unchanged during the study.

124 Two participants (15 and 16) in the study were happy with their pubertal development after

125 18 months of intramuscular testosterone and stopped injections but completed all

126 scheduled visits. These are highlighted with * in figures and tables.

127 **Treatment satisfaction for medication questionnaire**

128 The mean total TSQM was 48.5 (SD 6.2, range 37-59) out of a possible 59 points, with similar
129 scores in each domain (Table III and Figure I). To the nearest integer, the mean score for all
130 but one treatment domain was 6 ('very satisfied'). When considering time to effect, the
131 mean score was 5 ('satisfied'). Two patients felt that they had experienced side-effects from
132 the IM testosterone regimen. Their responses corresponded with the adverse events profile
133 recorded by the study team (Supplementary Results).

134 **Pubertal status**

135 All patients were either Tanner stage G1P1, G2P1 or G1P2 and had a testicular volume of
136 <4mls at baseline. Initial testosterone levels were < 2.0nmol/l with suppressed LH and FSH
137 levels (median LH <0.1IU/L (IQR <0.1, 0.1), median FSH 1.2IU/L (IQR 1.1, 1.8)). By the 2-year
138 visit, patients were Tanner stage G4P4 to G5P5 and median testosterone level was 8.3nmol/l
139 (IQR 5.7-17.9) 3-5 weeks after their last injection. Testicular volume was ≤ 5mls in all (mean
140 2.8, SD 2.9, range 1.5-5 mls) after 2 years and LH/FSH levels remained suppressed (median
141 LH <0.1IU/L (IQR 0.1, 0.1), median FSH <0.1IU/L (IQR 0.1, 1.2)). By 3 months after the last
142 Sustanon injection, activation of the hypothalamo-pituitary axis (HPA) was evident with a
143 significant increase in both LH and FSH (median LH 6.7IU/L (IQR 5.9, 8.8), p<0.01, median
144 FSH 6.0IU/L (IQR 4.4, 8.0), p<0.01) compared to baseline. In keeping with this, the median
145 testosterone level 3 months after the last injection was 7.5nmol/l (IQR 5.5-12.8- available in
146 13/15 patients - two stopping treatment early). By 6-9 months after the last injection, the
147 testosterone level was 9.7nmol/l (IQR 5.7-11.1). Mean testicular volume 6-9 months after
148 last injection was 6.9ml (1.9), significantly greater than the baseline 2.2mls (SD 0.2; p<0.001).
149 In keeping with this, LH and FSH levels also remained significantly raised compared to
150 baseline at 5.3IU/l (IQR 3.2-5.9, p<0.001) and 7.9IU/L (IQR 5.1-10.4, p<0.001) respectively.

151 **Muscle function**

152 The mean NSAA score at baseline for ambulant participants was 13.7 (SD 9.8) (Table IV). The
153 mean PUL score at baseline was 33.9 (SD 6.7) and was not directly correlated with
154 ambulatory status (Table I). PUL score was 30.9 (SD 8.7) at final assessment which was no
155 different to baseline. Five participants lost ambulation during the 2-year study period, so
156 that only 8 completed the NSAA at the final visit. For those with initial and final NSAA scores,
157 mean initial NSAA score was 18.0 (SD 8.9, range 6-30) and final NSAA score 13.0 (SD 7.2,
158 range 4-24).

159 **Anthropometric variables**

160 Baseline height z-score was -3.17 (SD 1.34) and -3.44 (SD 1.06) after 2 years. The mean 2-
161 year height gain was 8.8 cm (SD 5.2). The baseline BMI z-score was 2.16 (SD 0.90) with a
162 mean change of -0.45 (SD -3.2) over 2 years, giving a final BMI z-score of 1.64 (SD 1.35).
163 There was no change in fat mass or lean mass index during the study (Table IV, Figure III).

164 **Bone mineral density**

165 Initial lumbar spine size adjusted z-score was 0.22 (SD 2.21). After 2 years of testosterone
166 treatment, the lumbar spine size-adjusted z-score was 0.35 (SD 2.21).

167 **Bone age**

168 Bone age advanced in all patients during the study period (Tables I and II); mean change was
169 3.0 years (SD 1.7).

170 **Muscle MRI**

171 ***Cross-sectional comparison of DMD participants vs controls***

172 Data were obtained from the legs of 5 healthy controls and the arms of 6 healthy controls.
173 Arm and leg muscle MRI data was obtained for 14 DMD participants who attended at
174 baseline, 1 year and 2 years.

175 For leg muscle groups, the muscle FF was higher in DMD participants than controls ($p =$
176 <0.001 , Table VI), with a wide variation in leg muscle pathology of individuals (Figure IVA).
177 The tibial bone marrow FF of DMD boys was also higher than controls at baseline (99.3% vs
178 88.9%, $p = 0.02$, Table VI).
179 All arm muscles had higher FF for DMD participants than controls ($p <0.01$, Table VII). The
180 extent of arm muscle involvement varied considerably between individuals (Figure IVB). T2
181 relaxation times were higher in DMD patients at baseline (p values <0.01) than controls
182 (Table VII). The difference between T2 times of participants and controls at baseline was
183 least marked for the UFG (1.3ms vs 2.6-3.0ms, Table VII).

184 ***Longitudinal changes in MRI data***

185 The bone marrow FF was constant over time (Table VI). There were no significant
186 longitudinal changes in mean FF of any individual leg muscle (Table VI), and when leg muscle
187 groups were combined, there were no significant changes in FF during the 2-year period.
188 When all muscle groups were combined, there were significant increases in both CSA and
189 cCSA between baseline and 2 years ($p <0.001$ and $p <0.01$ respectively). When CSA of
190 combined muscle groups for individuals was analysed, 8 participants had a significant change
191 in CSA over 2-years. By individual muscle group, cCSA only increased in TA.

192 ***Longitudinal changes in MRI arm data***

193 There was a significant increase in FF of the UFG (Table VII) over the 2-year period. Arm FF
194 remained unchanged in most participants/muscle groups over the 2-year period (Table VII
195 and Figure IVB). When all arm muscle groups were combined, both CSA and cCSA increased
196 ($p = 0.004$ and $p = 0.05$). The CSA was greater in all four muscle groups at 2 years (Table VII)..
197 The only significant change in arm cCSA over time was in the FEG, with increases at 1 and 2
198 years compared to baseline (Table VII).

199 The T2 relaxation times for all groups except UFG decreased significantly at 2 years post-
200 baseline but remained higher than controls (Table VII).

201

202 **Discussion**

203 The newly revised standards of care highlight the importance of the timely recognition and
204 management of pubertal delay in DMD (19) and this is the first study that has prospectively
205 evaluated pubertal induction in adolescents with DMD. Our data support the use of
206 androgen in DMD boys on GC with evidence of benefit in many of the parameters studied.
207 Monthly incremental injections of Sustanon were well tolerated with adolescents being
208 mainly 'very satisfied'. The participant who awarded a value of 1 to the question, "Is the
209 treatment easy to use?" probably did so in error, as they awarded the maximum score of 7
210 to the other questions. The only domain in which the score was lower was 'time to work'
211 where participants were 'satisfied'.

212

213 All patients were in late puberty after 2 years. The increase in gonadotropin levels and
214 testicular volume, which occurred by 3 months and persisted at 6-9 months after the last
215 Sustanon injection, suggested activation of the hypothalamo-pituitary gonadal (HPG) axis
216 and endogenous testosterone production after the cessation of exogenous testosterone.
217 There was variability in terms of testicular volume, androgen and gonadotrophin levels,
218 suggesting that there may be additional factors affecting the HPG axis including relative
219 sensitivity to GC (20, 21). It will be important to determine their ongoing gonadal and
220 androgen status.

221

222 There was a mean height increase of 8cm over 2 years, substantially more than the median
223 height velocity of only 0.45cm/year in the year preceding pubertal induction described
224 previously in DMD (8). Short stature is a key concern in this population (6), and many
225 adolescents would like to be taller and look more like their peers. Whilst a large height gain
226 may not be advantageous (22), a small height gain during puberty is likely to be welcomed
227 by the patients.

228

229 Delayed bone age in adolescents with DMD is multi-factorial, but largely related to delayed
230 puberty and growth retardation (23, 24). Bone age increased at a greater rate than
231 chronological age suggesting that epiphyseal maturation was taking place despite the
232 presence of pharmacological doses of GC.

233

234 Low BMD and fracture are well-recognised complications in DMD, both as a consequence of
235 the disease process itself and chronic GC use. Although this study was not powered to look
236 in detail at bone health or body composition, it appears that the testosterone regimen
237 stabilised BMD. However, as shown in Figure III, there was wide variability, with some
238 participants having a marked increase in BMD, whilst others remained stable or decreased.
239 Studies have shown that BMD decreases with age and GC use in DMD and falls further still
240 when boys lose ambulation (25, 26, 27, 28). The process of puberty is vital for an increase in
241 bone size and bone mineral content. Androgen deficiency is a risk factor for osteoporosis
242 and fracture and early initiation of androgen therapy is associated with improved bone
243 mineral density (29). Although fracture risk does not correlate directly with BMD, these data
244 suggest a possible bone protective effect of testosterone therapy, despite ongoing GC use.
245 Many boys lose ambulation after they fall and fracture and if muscle mass and bone density

246 can be optimised during puberty, ambulation may be maintained for longer. The change in
247 mean PUL score over two years is consistent with published data (-3 points), (30) whereas
248 the fall in mean NSAA score was slightly less than reported in the literature - mean drop of 4
249 points a year (31).

250

251 When arm muscle groups were combined, there were significant increases in both CSA and
252 cCSA from baseline to 2 years. Only one participant (participant 7, non-ambulant at baseline)
253 had a significant increase in overall FF of the arm. The arm FF remained unchanged over the
254 2-year period, in contrast to the natural history of DMD. Our data contrast with a recent
255 study of 15 non-ambulant boys with DMD (mean age 13.3 years) which found a progressive
256 increase in FF (18). Only 7 boys completed that study and pubertal status was not recorded.

257

258 When leg muscle groups were combined and compared between baseline and 2 years, there
259 were also increases in both CSA and cCSA. FF in most participants and muscle groups were
260 stable over the 2-year study period and only increased in one participant. This challenges
261 the results found in other studies (32, 33).

262

263 The CSA of all four muscle groups in the arm increased significantly over 2 years, showing
264 the muscle growth that we would expect. The cCSA (that area which is not fat replaced) on
265 the other hand only increased significantly for the FEG, suggesting that in this muscle group
266 the growth of muscle volume outpaced the disease process, whereby fat replaces muscle
267 and the FF results support this. When all muscle groups were considered together, there was
268 no significant increase in fat fraction and significant increases in CSA and cCSA for arm and
269 legs: muscle growth at least kept pace with chronic destruction. By contrast, the cCSA did

270 not significantly increase in any of the arm muscle groups studied by Ricotti et al (18).

271

272 The mean FF of the tibial bone marrow for the DMD boys was significantly higher than
273 controls (Table III). Many factors may contribute to BMD reduction including progressive
274 muscle weakness and GC use, which cause increased bone marrow adiposity (34, 35),
275 probably through a diversion in the mesenchymal progenitor cell line with increased
276 adipogenesis (36, 37). Bone marrow FF has been suggested as a potential biomarker in
277 postmenopausal women with fragility fractures (38).

278

279 The T2 relaxation times of all four compound muscle groups were significantly higher at
280 baseline than controls, in keeping with an ongoing inflammatory process. This observation is
281 consistent with some studies (39) but contrasts with others (32). The relaxation times for all
282 groups except UFG (which was the least affected at baseline) decreased significantly at 2
283 years but remained higher than those of the controls at baseline. This may indicate a
284 reduction in the inflammatory process after testosterone supplementation, as similar results
285 have been demonstrated after 3 months of GC therapy in DMD (40). Androgens are known
286 to have an anti-inflammatory effect, partly via their role in cytokine-suppression (41, 42) and
287 may have a disease-ameliorating role in addition to the more well characterised benefits of
288 testosterone during puberty. It is possible, however, that T2 relaxation time may decrease
289 once a boy loses ambulation and 5 boys lost ambulation over 2 years.(32).

290

291 **Limitations of the study**

292 Although we wanted to perform a randomised double-blinded clinical trial, the Research

293 Ethic Committee felt that it would be inappropriate to withhold treatment for a period of 2

294 years in this cohort, particularly as our audit suggested that it was well-liked (8).
295 Furthermore, physical development during puberty precludes the use of a placebo. By
296 standardising the regimen, investigations and collection of the adverse event profile and
297 safety data that are required as part of a rigorous clinical trial methodology, this has enabled
298 us to systematically evaluate the tolerability and efficacy of this regimen. The study was
299 small, and the recruitment target was pragmatic within a 1 year window at our centre. It was
300 therefore underpowered to detect differences in some of the secondary outcomes such as
301 BMAD and body composition.

302

303 **Conclusion**

304 A 2-year incremental regimen of 4-weekly intramuscular testosterone injections in pre-
305 pubertal boys with DMD was safe, well tolerated, associated with high satisfaction scores
306 and resulted in endogenous gonadotropin release when exogenous testosterone was
307 stopped. Height increased in most individuals and there was evidence to suggest a
308 favourable impact on bone density, muscle morphology and muscle function. Our data
309 support the routine use of exogenous androgen in boys with DMD who are on GC, as
310 recommended in the revised DMD standards of care. It is unclear whether endogenous
311 testosterone production will remain adequate in the longer term.

312

313 **Declaration of Interest**

314 Volker Straub has received speaker honoraria from Sanofi Genzyme and is or has recently
315 been on advisory boards for Audentes Therapeutics, AveXis, Biogen, Exonics
316 Therapeutics/Vertex, Roche, Sarepta Therapeutics and Wave Therapeutics. He has research
317 collaborations with Ultragenyx and Sanofi Genzyme.

318 Robert Muni Lofra has received speaker honoraria from Biogen and has been recently on
319 advisory boards for Roche and Biogen.

320 Anna Mayhew has participated in SAB meetings for Summit, PTC and Biogen and performs
321 Consultancy work (training physiotherapists) for: Roche, Pfizer, PTC, Summit, Sarepta,
322 Santhera, Italfarmaco, Amicus, Biogen and Avexis.

323 Michela Guglieri has received speaker honoraria from Sarepta and is or has been on advisory
324 boards for PTC Therapeutics and Pfizer.

325 Claire Wood, Kieren Hollingsworth, Eric Hughes, Sadha Punniyakodi, Rod Mitchell and Tim
326 Cheetham have no conflicts of interest.

327

328 **Funding**

329 The study was generously funded by Duchenne Now. CW was funded by the Medical
330 Research Council/MDUK (MR/N020588/1). EH was funded by the European Commission
331 Horizon 2020 (Grant no. 667078)

332

333 **Acknowledgements**

334 With thanks to:

- 335 • The participants and their families for giving up their time to take part in this study.
- 336 • Yolanda Ailins-Sahun, Jonathan Foggin, Meredith James, Dionne Moat, Jas Sodhi, the
337 nursing staff in the CRF and the Clinical trials unit at Newcastle University for their
338 help in collecting and analysing data
- 339 • Simon Pearce, Terry Aspray, Cathy Turner and Pauline McCormack for their roles in
340 the Testosterone Steering Committee.

- 341 • Tim Hodgson, Dot Wallace and Louise Ward, Senior Research Radiographers at the
342 Newcastle Magnetic Resonance Centre for acquiring the MRI data.

343

344 **References**

345

- 346 1. Emery AE. Population frequencies of inherited neuromuscular diseases--a world
347 survey. *Neuromuscul Disord* 1991 **1** 19–29.
- 348 2. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ,
349 Dickson JG, Tinsley JM, Davies KE, & Holloway R. Utrophin-dystrophin-deficient mice
350 as a model for Duchenne muscular dystrophy. *Cell* 1997 **90** 717–727.
- 351 3. Moxley RT, Pandya S, Ciafaloni E, Fox DJ, & Campbell K. Change in natural history of
352 Duchenne muscular dystrophy with long-term corticosteroid treatment: implications
353 for management. *J Child Neurol* 2010 **25** 1116–1129.
- 354 4. Daftary AS, Crisanti M, Kalra M, Wong B, & Amin R. Effect of long-term steroids on
355 cough efficiency and respiratory muscle strength in patients with Duchenne muscular
356 dystrophy. *Pediatrics* 2007 **119** e320-4.
- 357 5. Lebel DE, Corston JA, McAdam LC, Biggar WD, & Alman BA. Glucocorticoid treatment
358 for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-
359 term follow-up. *J Bone Joint Surg Am* 2013 **95** 1057–1061.
- 360 6. Wood CL, Straub V, Guglieri M, Bushby K, & Cheetham T. Short stature and pubertal
361 delay in Duchenne muscular dystrophy. *Arch Dis Child* 2015 **101** 101–106.
- 362 7. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull
363 L, Callegari C, & Swerdloff RS. Testosterone replacement therapy improves mood in
364 hypogonadal men--a clinical research center study. *J Clin Endocrinol Metab* 1996 **81**

- 365 3578–3583.
- 366 8. Wood CL, Cheetham T, Guglieri M, Bushby K, Owen C, Johnstone H, & Straub V.
367 Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy.
368 *Neuropediatrics* 2015 **46** 371–376.
- 369 9. Wood CL, Cheetham TD, Hollingsworth KG, Guglieri M, Ailins-Sahun Y, Punniyakodi S,
370 Mayhew A, & Straub V. Observational study of clinical outcomes for testosterone
371 treatment of pubertal delay in Duchenne muscular dystrophy. *BMC Pediatrics* 2019 **19**
372 131.
- 373 10. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, & Rowland CR.
374 Validation of a general measure of treatment satisfaction, the Treatment Satisfaction
375 Questionnaire for Medication (TSQM), using a national panel study of chronic disease.
376 *Health Qual Life Outcomes* 2004 **2** 12.
- 377 11. Marshall WA & Tanner JM. Variations in the pattern of pubertal changes in boys. *Arch*
378 *Dis Child* 1970 **45** 13–23.
- 379 12. Greulich WW & Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and
380 Wrist. edn 2nd, California: Stanford University Press,1959.
- 381 13. Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, Vandenhauwe M,
382 Klingels K, Florence J, Main M, Bianco F, Henrikson E, Servais L, Champion G, Vroom E,
383 Ricotti V, Goemans N, McDonald C, & Mercuri E. Development of the Performance of
384 the Upper Limb module for Duchenne muscular dystrophy. *Dev Med Child Neurol*
385 2013 **55** 1038–1045.
- 386 14. Mayhew AG, Cano SJ, Scott E, Eagle M, Bushby K, Manzur A, & Muntoni F. Detecting
387 meaningful change using the North Star Ambulatory Assessment in Duchenne
388 muscular dystrophy. *Dev Med Child Neurol* 2013 **55** 1046–1052.

- 389 15. Hollingsworth KG, Higgins DM, McCallum M, Ward L, Coombs A, & Straub V.
390 Investigating the quantitative fidelity of prospectively undersampled chemical shift
391 imaging in muscular dystrophy with compressed sensing and parallel imaging
392 reconstruction. *Magnetic Resonance in Medicine* 2014 **72** 1610–1619.
- 393 16. Loughran T, Higgins DM, McCallum M, Coombs A, Straub V, & Hollingsworth KG.
394 Improving Highly Accelerated Fat Fraction Measurements for Clinical Trials in
395 Muscular Dystrophy: Origin and Quantitative Effect of R2* Changes. *Radiology* 2015
396 **275** 570–578.
- 397 17. Carlier PG. Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles:
398 Different methodology, different information and different implications.
399 *Neuromuscular Disorders* 2014. pp 390–392. .
- 400 18. Ricotti V, Evans MRB, Sinclair CDJ, Butler JW, Ridout DA, Hogrel JY, Emira A, Morrow
401 JM, Reilly MM, Hanna MG, Janiczek RL, Matthews PM, Yousry TA, Muntoni F, &
402 Thornton JS. Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water
403 Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials.
404 *PLOS ONE* 2016 **11** e0162542.
- 405 19. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE,
406 Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM,
407 Weber DR, & DMD Care Considerations Working Group. Diagnosis and management
408 of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular,
409 rehabilitation, endocrine, and gastrointestinal and nutritional management. *The*
410 *Lancet Neurology* 2018 **17** 251–267.
- 411 20. Sakakura M, Takebe K, & Nakagawa S. Inhibition of luteinizing hormone secretion
412 induced by synthetic LRH by long-term treatment with glucocorticoids in human

- 413 subjects. *Journal of Clinical Endocrinology and Metabolism* 1975 **40** 774–779.
- 414 21. MacAdams MR, White RH, & Chipps BE. Reduction of serum testosterone levels
415 during chronic glucocorticoid therapy. *Annals of Internal Medicine* 1986 **104** 648–651.
- 416 22. Biggar WD, Harris VA, Eliasoph L, & Alman B. Long-term benefits of deflazacort
417 treatment for boys with Duchenne muscular dystrophy in their second decade.
418 *Neuromuscul Disord* 2006 **16** 249–255.
- 419 23. Annexstad EJ, Bollerslev J, Westvik J, Myhre AG, Godang K, Holm I, & Rasmussen M.
420 The role of delayed bone age in the evaluation of stature and bone health in
421 glucocorticoid treated patients with Duchenne muscular dystrophy. *International*
422 *Journal of Pediatric Endocrinology* 2019 **2019** 4.
- 423 24. Al-Zougbi A, Mathews KD, & Shibli-Rahhal A. Use of bone age for evaluating bone
424 density in patients with Duchenne muscular dystrophy: A preliminary report. *Muscle*
425 *& Nerve* 2019 **59** 422–425.
- 426 25. Larson CM & Henderson RC. Bone mineral density and fractures in boys with
427 Duchenne muscular dystrophy. *J Pediatr Orthop* 2000 **20** 71–74.
- 428 26. McDonald DG, Kinali M, Gallagher AC, Mercuri E, Muntoni F, Roper H, Jardine P, Jones
429 DH, & Pike MG. Fracture prevalence in Duchenne muscular dystrophy. *Dev Med Child*
430 *Neurol* 2002 **44** 695–698.
- 431 27. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, &
432 Kissel JT. Orthopedic outcomes of long-term daily corticosteroid treatment in
433 Duchenne muscular dystrophy. *Neurology* 2007 **68** 1607–1613.
- 434 28. James KA, Cunniff C, Apkon SD, Mathews K, Lu Z, Holtzer C, Pandya S, Ciafaloni E, &
435 Miller L. Risk Factors for First Fractures Among Males With Duchenne or Becker
436 Muscular Dystrophy. *Journal of Pediatric Orthopaedics* 2015 **35** 640–644.

- 437 29. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, & Klibanski A.
438 Increase in bone density and lean body mass during testosterone administration in
439 men with acquired hypogonadism. *J Clin Endocrinol Metab* 1996 **81** 4358–4365.
- 440 30. Mayhew AG, Coratti G, Mazzone ES, Klingels K, James M, Pane M, Straub V, Goemans
441 N, Mercuri E, Ricotti V, Muntoni F, Ridout D, & Selby V. Performance of Upper Limb
442 module for Duchenne muscular dystrophy. *Developmental Medicine and Child*
443 *Neurology* 2019 .
- 444 31. Mercuri E, Coratti G, Messina S, Ricotti V, Baranello G, D’Amico A, Pera MC,
445 Albamonte E, Sivo S, Mazzone ES, Arnoldi MT, Fanelli L, Sanctis R De, Romeo DM, Vita
446 GL, Battini R, Bertini E, Muntoni F, & Pane M. Revised north star ambulatory
447 assessment for young boys with Duchenne muscular dystrophy. *PLoS ONE* 2016 **11**
448 e0160195.
- 449 32. Wary C, Azzabou N, Giraudeau C, Louër J Le, Montus M, Voit T, Servais L, & Carlier P.
450 Quantitative NMRI and NMRS identify augmented disease progression after loss of
451 ambulation in forearms of boys with Duchenne muscular dystrophy. *NMR in*
452 *Biomedicine* 2015 **28** 1150–1162.
- 453 33. Hogrel JY, Wary C, Moraux A, Azzabou N, Decostre V, Ollivier G, Canal A, Lilien C,
454 Ledoux I, Annoussamy M, Reguiba N, Gidaro T, Moing AG Le, Cardas R, Voit T, Carlier
455 PG, & Servais L. Longitudinal functional and NMR assessment of upper limbs in
456 Duchenne muscular dystrophy. *Neurology* 2016 **86** 1022–1030.
- 457 34. Li GW, Xu Z, Chen QW, Chang SX, Tian YN, & Fan JZ. The temporal characterization of
458 marrow lipids and adipocytes in a rabbit model of glucocorticoid-induced
459 osteoporosis. *Skeletal Radiology* 2013 **42** 1235–1244.
- 460 35. Lovdel A, Suchacki K, Sulston RJ, Wallace RJ, Macpherson G, Stimson RH, Homer NZ,

- 461 Chapman KE, & Cawthorn WP. Investigating glucocorticoids as mediators of increased
462 bone marrow adiposity during caloric restriction. *Endocrine Abstracts* 2018 .
- 463 36. Ito S, Suzuki N, Kato S, Takahashi T, & Takagi M. Glucocorticoids induce the
464 differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and
465 osteoblasts, but fail to induce terminal osteoblast differentiation. *Bone* 2007 **40** 84–
466 92.
- 467 37. Tencerova M & Kassem M. The Bone Marrow-Derived Stromal Cells: Commitment and
468 Regulation of Adipogenesis. *Frontiers in endocrinology* 2016 **7** 1–12.
- 469 38. Paccou J, Hardouin P, Cotten A, Penel G, & Cortet B. The role of bone marrow fat in
470 skeletal health: Usefulness and perspectives for clinicians. *Journal of Clinical*
471 *Endocrinology and Metabolism* 2015 **100** 3613–3621.
- 472 39. Willcocks RJ, Triplett WT, Forbes SC, Arora H, Senesac CR, Lott DJ, Nicholson TR,
473 Rooney WD, Walter GA, & Vandeborne K. Magnetic resonance imaging of the
474 proximal upper extremity musculature in boys with Duchenne muscular dystrophy
475 HHS Public Access. *J Neurol* 2017 **264** 64–71.
- 476 40. Arpan I, Willcocks RJ, Forbes SC, Finkel RS, Lott DJ, Rooney WD, Triplett WT, Senesac
477 CR, Daniels MJ, Byrne BJ, Finanger EL, Russman BS, Wang DJ, Tennekoon GI, Walter
478 GA, Sweeney HL, & Vandeborne K. Examination of effects of corticosteroids on
479 skeletal muscles of boys with DMD using MRI and MRS. *Neurology* 2014 **83** 974–980.
- 480 41. Bianchi VE. The Anti-Inflammatory Effects of Testosterone. *Journal of the Endocrine*
481 *Society* 2019 **3** 91–107.
- 482 42. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, & Jones TH. The Effect of
483 Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles
484 in Hypogonadal Men. *The Journal of Clinical Endocrinology & Metabolism* 2004 **89**

485 3313–3318.

486

487

	Overall	Ambulant (n=12)	Non-ambulant (n=3)
	Mean (SD)		
Age at baseline (years)	13.8 (1.50)	13.7 (1.42)	14.4 (1.99)
Bone age at baseline (years)	9.4 (2.2)	9.1 (2.2)	10.5 (2.3)
Time on steroids (years)	8.4 (2.2)	8.4 (1.2)	8.7 (4.9)
Deflazacort dose (mg/kg) n=9	0.55 (0.13)	0.56 (0.14)	0.44 (-)
Prednisolone dose (mg/kg) n=6	0.47 (0.13)	0.51 (0.15)	0.41 (0.11)
North Star Ambulatory Assessment score (NSAA)	13.7 (9.8)	13.7 (9.8)	-
Performance of the upper limb (PUL) score	33.9 (6.7)	34.3 (7.1)	32.7 (6.1)

489 **Table I** Baseline characteristics of participants

	Initial age (years)	Initial bone age (years)	Final age (years)	Final bone age (years)	Change in bone age (years)	GC regimen	GC daily dose (mg/kg)	Initial NSAA	Final NSAA	Initial PUL	Final PUL
1	14.75	8	16.75	12.5	4.5	D daily	0.52	7	8	36	31
2	13.33	8	15.33	11	3	P daily	0.67	4	NA	26	17
4	14.75	11	16.75	12.5	1.5	P daily	0.59	11	NA	41	34
5	12.42	12.5	14.42	14	1.5	D daily	0.44	NA	NA	34	39
6	14.50	8	16.50	11	3	P daily	0.33	NA	NA	38	29
7	16.33	11	18.33	12.5	1.5	P daily	0.48	NA	NA	26	20
8	12.08	6	14.08	8	2	D daily	0.5	16	17	40	41
9	12.33	10	14.33	12.5	2.5	D daily	0.49	30	24	42	42
10	16.83	12	18.83	12.5	0.5	D daily	0.69	4	NA	20	22
11	12.83	9.5	14.83	14.5	5	P 10 on/off	0.38	23	21	41	38
12	14.17	6	16.17	11.5	5.5	D daily	0.69	13	4	28	22
13	14.83	10	16.83	13.5	3.5	P daily	0.38	23	14	40	41
14	12.25	12.5	14.25	14	1.5	D daily	0.3	1	NA	31	21
15*	13.08	9	15.08	13	4	D daily	0.62	26	10	31	36
16*	13.08	7	15.08	13	6	D daily	0.69	6	6	35	31

Table II Individual patient characteristics D: deflazacort, P: prednisolone, NSAA: North Star ambulatory assessment, PUL: performance of the upper limb. * signifies the 2 patients that chose to stop testosterone treatment after 18 months

	Q1 (1-7)	Q2(1-7)	Q3 (1-7)	Q4 (yes/no)	Q5 (1-5)	Q6 (1-5)	Q7 (1-5)	Q8 (1-5)	Q9 (1-7)	Q10 (1-7)	Q11 (1-7)	Q12 (1-5)	Q13 (1-5)	Q14 (1-7)
	Effectiveness			Side-effects					Convenience			Global satisfaction		
1	7	7	6	No					6	6	5	5	5	7
2	7	7	5	No					6	6	6	4	No data	7
4	7	7	7	No					7	5	5	4	3	6
5	6	6	6	Yes	2	1	1	1	6	6	2	4	5	7
6	7	7	7	No					7	7	7	5	5	7
7	5	4	5	No					6	5	5	3	3	5
8	4	3	5	No					6	6	7	4	3	5
9	7	7	7	No					7	7	6	5	5	7
10	6	4	5	No					7	7	7	3	3	5
11	6	6	6	No					6	6	6	4	3	6
12	6	6	6	Yes	1	1	1	1	6	6	5	5	5	6
13	6	6	5	No					6	5	5	4	4	7
14	5	5	5	No					7	7	6	5	5	7
15*	4	7	5	No					5	5	5	3	2	5
16*	4	4	2	No					1	7	7	3	3	7

Table III TSQM questionnaire data. Q4 is a dichotomous response option with a conditional skip to Q9. Where a scale of 1-7 was used, 1 indicates ‘extremely dissatisfied’, 7 indicates ‘extremely satisfied’. Within the scale of 1-5, 1 indicates ‘not at all’ while 5 indicates ‘extremely’.

	Initial T	Initial LH	Initial FSH	Initial testic vol (mean)	Initial Tanner stage	T at end of regimen	LH at end of regimen	FSH at end of regimen	Testic vol at end	Tanner stage at end	T 3 m after	LH 3 m after	FSH 3m after	T 6-9m after	LH 6-9 m after	FSH 6-9 m after	Testic vol 6-9m after
1	0.1	<0.1	1.1	1.5	G1P1	10	0.1	1.4	1.5	G5P4	15.2	8.8	3.6	14.7	3.2	5.5	4.75
2	0.1	<0.1	1.3	2	G1P2	18.7	0.1	0.1	2.5	G4P4	21.8	5	1.8	11.1	3.6	2.5	10
4	1.9	3.3	3.8	3.5	G2P1	10.3	4.9	13.1	3	G4P4	19.5	6.2	11.2	9.7	3.2	11.1	8
5	0.1	<0.1	0.5	1.5	G1P1	8.3	0.1	0.1	3	G4P4	7.5	9.8	4.4	5.7	2.6	4	8
6	0.1	1.6	7.7	3	G1P2	17.9	0.1	0.1	4	G4P4	12.1	25.1	38.3	11.7	13.7	32.9	5
7	0.1	<0.1	1.8	3.75	G1P1	5.2	0.5	0.1	3	G4P5	6.6	5.9	13.4	5.1	8.4	12.6	8
8	0.1	<0.1	1.2	1.5	G1P2	20.7	0.1	0.1	3	G5P5	8.7	6.7	6.7	9.7	5.9	6.5	4
9	0.1	<0.1	<0.1	2	G1P1	5.7	0.1	1.2	2	G5P4	5.5	7.6	8	7.9	5.3	8.6	10
10	0.1	<0.1	<0.1	1.5	G1P2	6.9	0.1	0.1	2.5	G5P4	1.9	0.1	3.9	3.8	13.5	9.1	4
11	0.1	<0.1	<0.1	2	G1P1	6.8	0.1	0.1	3	G5P5	6.7	6	6	10.1	5.5	8.4	-
12	0.1	<0.1	1.1	2	G1P1	8.9	0.1	0.1	5	G5P5	11.7	7.8	5.9	9.8	4.2	5.1	5
13	0.1	<0.1	1.1	2	G2P2	7.4	0.1	0.7	2	G4P4	6.9	10.1	3.6	8.3	3.1	2.0	-
14	0.1	<0.1	1.3	1.5	G1P1	31.4	0.1	0.1	2.75	G5P5	1.3	2.3	1.8	4.9	5.7	10.4	-
15*	0.1	<0.1	3.9	3.25	G2P1	4	0.1	0.1	2	G4P4	-	-	-	4.8	2.9	7.8	7.5
16*	0.1	<0.1	1.1	2	G1P2	5.2	6.4	7.2	3	G5P5	-	-	-	12.8	5.3	7.9	6

Table IV Pubertal characteristics * signifies the 2 patients that chose to stop testosterone treatment after 18 months. T measured in nmol/l, FSH and LH in IU/L, testicular volume in mls (mean of left and right volumes).

	Before Testosterone	After Testosterone
	Mean (SD)	
Height (cm)	133.6 (10.7)	142.4 (7.4)
Height z-score	-3.17 (1.34)	-3.44 (1.06)
Target height (cm)	183.3 (4.6)	
Weight (kg)	48.3 (12.4)	52.8 (12.2)
Weight z-score	-0.19 (1.56)	-0.94 (1.81)
BMI (kg/m ²)	26.8 (4.5)	26.3 (5.0)
BMI z-score	2.16 (0.9)	1.64 (1.35)
Lean mass index (kg/m ²)	12.4 (2.3)	12.8 (2.9)
Fat mass index (kg/m ²)	13.6 (4.2)	12.5 (4.3)
NSAA (if ambulant at both timepoints)	18 (8.88)	13 (7.23)
PUL	33.9 (6.72)	30.9 (8.66)
LS BMAC z-score	0.22 (2.21)	0.35 (2.21)

Table V Outcome variables before and after a 2-year incremental regimen of intramuscular testosterone.

Muscle group	DMD bl FF,%	DMD 1y FF,%	DMD 2y FF,%	Control FF,%	DMD bl CSA,mm ²	DMD 2y, CSA,mm ²	DMD bl, cCSA,mm ²	DMD 2y, cCSA,mm ²
BM	99.3	99.3	99.2	88.9*	-	-	-	-
TA	11.7	11.2	11.9	2.0†	296	383†	265	343†
MG	23.6	22.7	22.6	2.8§	1216	1374	942	1090
LG	28.7	28.0	28.5	2.5§	549	644	371	443
SOL	19.1	20.1	21.5	2.4‡	1566	1611	1261	1274
RF	51.9	53.9	51.5	1.6§	500	548	237	258
VL	50.8	51.5	51.8	2.0§	994	1069	489	515
BFLH	59.5	61.4	62.0	2.7§	839	856	316	335
ST	28.2	27.8	32.7	2.7‡	508	612†	375	425
SART	24.9	26.1	27.5	5.1§	215	244*	163	178
TOTAL	33.9	34.1	33.8	2.4‡	6683	7341‡	4419	4861†

Table VI Longitudinal results for fat fraction (FF), cross-sectional area (CSA) and contractile cross-sectional area (cCSA) when each muscle group is considered separately for 14 participants.* p < 0.05, † p < 0.01, ‡ p < 0.001, § p < 0.0001 – p values in the control column are unpaired t-tests vs DMD baseline, p values in DMD 1 y and 2y are paired tests vs DMD baseline. Abbreviations : BM: bone marrow, TA: tibialis anterior, MG: medial gastrocnemius, LG: lateral gastrocnemius, SOL: soleus, RF: rectus femoris, VL: vastus lateralis, BFLH: biceps femoris long head, ST: semitendinosus, SART: sartorius.

Muscle group	DMD bl T2,ms	DMD 1y T2,ms	DMD 2y T2,ms	Control T2,ms	DMD bl FF,%	DMD 1y FF,%	DMD 2y FF,%	Control FF,%	DMD bl CSA,mm ²	DMD 2y, CSA,mm ²	DMD bl, cCSA,mm ²	DMD 2y, cCSA,mm ²
FEG (<i>n</i> =12)	31.0	31.0	29.5‡	28.3§	11.5	10.3	11.5	3.9‡	397	501*	354	450*
UEG (<i>n</i> =12)	32.4	32.1	31.2†	29.5‡	13.6	16.1	18.8	3.4†	865	960*	749	808
FFG (<i>n</i> =12)	31.5	31.2	29.6†	28.5§	13.2	12.8	13.3	3.7†	849	911*	762	815
UFG (<i>n</i> =13)	30.4	30.2	30.2	29.1*	17.0	21.2	24.8*	3.6†	564	630*	480	490
TOTAL					12.3	11.8	14.6	3.6*	2675	3002†	2345	2563*

Table VII Longitudinal results for fat fraction (FF, %), mean T2 relaxation time (ms), cross-sectional area (CSA, mm²) and contractile cross-sectional area (cCSA, mm²), when each muscle group is considered separately for the participants. * p < 0.05, † p < 0.01, ‡ p < 0.001, § p < 0.0001 – p values in the control column are unpaired t-tests vs DMD baseline, p values in DMD 1 y and 2y are paired tests vs DMD baseline. Abbreviations: FEG: forearm extensor group, UEG: upper arm extensor group, FFG: forearm flexor group, UFG: upper arm flexor group